Compare Aurora Cannabis Inc (ACB) vs Futu Holdings Ltd (FUTU) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

FUTU trades at $94.03, down 1.06% on the day, with a neutral technical signal and bearish moving averages. The company reported strong revenue growth to $22.85B in 2025 and a net income margin of 41.83%, but faces multiple securities class action lawsuits alleging fraud related to undisclosed regulatory penalties. Valuation ratios appear attractive with a P/E of 10.85 and EV/EBITDA of 7.16.

The outlook is clouded by legal risks and mixed earnings performance, with recent misses on EPS estimates. Analyst consensus remains positive with 58% buy ratings, but investors must weigh solid fundamentals against significant litigation overhangs and regulatory scrutiny that could impact future performance.